Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q3 EPS of ($0.21), $0.06 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $375 thousand versus the consensus estimate of $50 thousand.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.